Sumitomo Pharma Switzerland GmbH
BiotechSumitomo Pharma Switzerland GmbH is a biotechnology company focused on Immunology.
Sumitomo Pharma Switzerland GmbH at a Glance
- Strong track record with 88% execution quality across 22 trials
- Fast trial execution (31 months median completion)
Sumitomo Pharma Switzerland GmbH's Key Drugs
Sumitomo Pharma Switzerland GmbH's core commercial portfolio centers on Rethymic, spanning Immunology — its most strategically important drugs approved in the last 15 years.
Sumitomo Pharma Switzerland GmbH's Recent FDA Approvals
New NDA/BLA approvals for Sumitomo Pharma Switzerland GmbH over the last two years — novel drugs only, excluding generics and label supplements.
Sumitomo Pharma Switzerland GmbH's Therapeutic Areas
Sumitomo Pharma Switzerland GmbH's approved drugs and pipeline span 1 therapeutic area, led by Immunology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
Sumitomo Pharma Switzerland GmbH's Top Competitors
Sumitomo Pharma Switzerland GmbH's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and AbbVie. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
Sumitomo Pharma Switzerland GmbH Pipeline Snapshot
Sumitomo Pharma Switzerland GmbH has 1 active clinical program from ClinicalTrials.gov — 0 Phase 3, 0 Phase 2 and 1 Phase 1.
Phase 3 Readout Calendar Pro
1 Phase 3 trial with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Rethymic leads revenue
- • Drug-level revenue analysis
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 8/9 completed
- • Speed: 31 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2021-10-07
- Latest
- 2021-10-07
- Applications
- 1
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges